SCHEMBL17708227

SCHEMBL17708227

[2H]C1(Oc2ccc(Nc3ncc(F)c(N[C@H]4CCN5[C@@H](CCC5(C)C)C4)n3)cc2-n2nnn(C)c2=O)CC(O)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 12/20 0.37
▸ ITK Q08881 4/20 0.36
▸ BCL6 P41182 1/20 0.36
▸ BTK Q06187 6/20 0.36
▸ PRKCQ Q04759 2/20 0.35
▸ AURKA O14965 2/20 0.35
▸ AURKB Q96GD4 2/20 0.35
▸ KDR P35968 2/20 0.35
▸ ALK Q9UM73 2/20 0.35
▸ CDK2 P24941 2/20 0.35
▸ SYK P43405 2/20 0.35
▸ CDC7 O00311 1/20 0.35
▸ PLK4 O00444 1/20 0.35
▸ CHEK1 O14757 1/20 0.35
▸ DCLK1 O15075 1/20 0.35
▸ PDPK1 O15530 1/20 0.35
▸ DAPK3 O43293 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ PRKD3 O94806 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19830202 0.94 EGFR (0.38) EGFRITKBCL6BTKPRKCQ
SCHEMBL15321579 0.88 EGFR (0.36) EGFRITKBCL6BTKPRKCQ
SCHEMBL17708229 0.85 BCL6 (0.47) EGFRITKBCL6BTKSYK
SCHEMBL15321006 0.81 PRKCQ (0.44) EGFRITKBCL6BTKPRKCQ
SCHEMBL15321009 0.81 PRKCQ (0.44) EGFRITKBCL6BTKPRKCQ
SCHEMBL15321473 0.81 EGFR (0.40) EGFRITKBCL6BTKPRKCQ
SCHEMBL15322084 0.80 EGFR (0.42) EGFRITKBCL6BTKPRKCQ
SCHEMBL16072519 0.80 EGFR (0.42) EGFRITKBCL6BTKPRKCQ
SCHEMBL15337509 0.80 EGFR (0.44) EGFRITKBCL6BTKPRKCQ
SCHEMBL15322494 0.80 EGFR (0.46) EGFRITKBCL6BTKPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2833889-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2017-11-01 — — EP claimed
US-9682976-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2017-06-20 — — US disclosed
US-20160257681-A1 Protein Kinase C Inhibitors and Uses Thereof MIDCAP FINANCIAL TRUST 2016-09-08 — — US disclosed
US-9321763-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2016-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257681-A1 Protein Kinase C Inhibitors and Uses Thereof PRKCH, PRKCA, PRKCB EGFR 2299/4885ITK 884/4885BCL6 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback